StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $0.28 | $0.31 | +9.78% | 1.9M |
| 05-13 | $0.32 | $0.36 | +13.59% | 1.7M |
| 05-14 | $0.36 | $0.41 | +12.72% | 1.1M |
| 05-15 | $0.40 | $0.36 | -9.32% | 0.6M |
| 05-18 | $0.38 | $0.41 | +7.53% | 4.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Fundamentals not available for SNGX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
No sell-side coverage available for SNGX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 | Annual 2020 2020-12-31 |
|---|---|---|---|---|
Revenue | $33.35K | $33.35K | $33.35K | $1.93M |
Operating Income | $-8.59M | $-5.22M | $-2.23M | $-18.59M |
Net Income | $-7.85M | $-4.26M | $-2.36M | $-17.69M |
EPS (Diluted) | $-0.20 | $-0.11 | $-0.06 | $-0.64 |
Total Assets | $29.72M | $29.61M | $31.55M | $19.89M |
Total Liabilities | $14.66M | $14.01M | $14.23M | $16.15M |
Cash & Equivalents | $28.87M | $28.98M | $30.54M | $18.68M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | $-11.46M |
Shares Outstanding | 42.63M | 40.08M | 40.02M | 30.64M |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.